Also entered into collaboration and option agreement with AbbVie to develop novel tumor-activated immunotherapies, including masked T cell engagers, with $52.0 million in upfront payments Extended ant ...

Also entered into collaboration and option agreement with AbbVie to develop novel tumor-activated immunotherapies, including masked T cell ...

CAR T-cell therapy for cancer leads to similar safety and cancer outcomes in patients with and without preexisting autoimmune ...

Researchers determine a complex immune infiltrate pattern based on a newly constructed immune map developed using pancreatic ...

A team from Osaka University has developed scSPOT, a new technique that reveals how immune cells called Tregs simultaneously ...

Doctors are enrolling patients in a groundbreaking clinical trial aimed at reducing cancer recurrence in patients with ...

A research team has made a major discovery on how the CUL5 gene affects CAR-T cell therapy, an advanced cancer therapy. The study reveals that reducing the activity of the CUL5 gene helps CAR-T cells ...

Researchers at the University of Liège (Belgium) have uncovered a previously unknown mechanism that regulates the immune ...

CARsgen Therapeutics Holdings Limited (Stock Code: 2171), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces that the first ...

A new study reveals that modifying the CUL5 gene enhances CAR-T cell therapy for leukemia and lymphoma. This improves cell ...

Researchers at the University of Liège (Belgium) have uncovered a previously unknown mechanism that regulates the immune ...